US Patent

US8921377 — Substituted 5-fluoro-1H-pyrazolopyridines and their use

Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2031-05-19 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel substituted 5-fluoro-1H-pyrazolopyridines and their use for treating and preventing cardiovascular disorders.

USPTO Abstract

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Drugs covered by this patent

Verquvo (VERICIGUAT) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3062`	—	Verquvo
`U-3062`	—	Verquvo
`U-3062`	—	Verquvo

Patent Metadata

Patent number: US8921377
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-19
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Intellectual Property GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.